PL3596125T3 - Przeciwciała anty-par2 i ich zastosowania - Google Patents
Przeciwciała anty-par2 i ich zastosowaniaInfo
- Publication number
- PL3596125T3 PL3596125T3 PL18714185.8T PL18714185T PL3596125T3 PL 3596125 T3 PL3596125 T3 PL 3596125T3 PL 18714185 T PL18714185 T PL 18714185T PL 3596125 T3 PL3596125 T3 PL 3596125T3
- Authority
- PL
- Poland
- Prior art keywords
- par2 antibodies
- par2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 | |
| PCT/EP2018/056776 WO2018167322A1 (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3596125T3 true PL3596125T3 (pl) | 2026-02-09 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18714185.8T PL3596125T3 (pl) | 2017-03-16 | 2018-03-16 | Przeciwciała anty-par2 i ich zastosowania |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10836822B2 (pl) |
| EP (2) | EP3596125B1 (pl) |
| JP (3) | JP7222901B2 (pl) |
| KR (1) | KR102711884B1 (pl) |
| CN (1) | CN110446720B (pl) |
| AU (3) | AU2018235031B2 (pl) |
| BR (1) | BR112019018752A2 (pl) |
| CA (1) | CA3055251A1 (pl) |
| CL (1) | CL2019002626A1 (pl) |
| CO (1) | CO2019010975A2 (pl) |
| CR (1) | CR20190417A (pl) |
| DK (1) | DK3596125T3 (pl) |
| ES (1) | ES3056721T3 (pl) |
| FI (1) | FI3596125T3 (pl) |
| HR (1) | HRP20251643T1 (pl) |
| IL (1) | IL269134B2 (pl) |
| LT (1) | LT3596125T (pl) |
| MA (1) | MA49886A (pl) |
| MX (1) | MX2019010802A (pl) |
| NZ (1) | NZ757915A (pl) |
| PH (1) | PH12019502087A1 (pl) |
| PL (1) | PL3596125T3 (pl) |
| PT (1) | PT3596125T (pl) |
| RS (1) | RS67581B1 (pl) |
| SG (1) | SG11201908056QA (pl) |
| SI (1) | SI3596125T1 (pl) |
| TW (1) | TWI788332B (pl) |
| UA (1) | UA125757C2 (pl) |
| WO (1) | WO2018167322A1 (pl) |
| ZA (1) | ZA201906004B (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| MX2019010802A (es) * | 2017-03-16 | 2019-10-30 | Medimmune Ltd | Anticuerpos anti-par2 y usos de los mismos. |
| US12214216B1 (en) | 2019-10-16 | 2025-02-04 | Helen Feng | Photon enhanced bone growth system and method |
| SMT202500106T1 (it) | 2020-08-18 | 2025-05-12 | Cephalon Llc | Anticorpi anti-par-2 e loro metodi d'uso |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| CN120835790A (zh) | 2023-01-25 | 2025-10-24 | 免疫医疗有限公司 | 偏头痛疗法 |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| WO2025191185A1 (en) | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| WO2004080373A2 (en) * | 2003-03-11 | 2004-09-23 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JP2008519039A (ja) * | 2004-11-04 | 2008-06-05 | ニュー イングランド メデカル センター ホスピタルズ インク | Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法 |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AR070911A1 (es) * | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US9315577B2 (en) | 2008-05-01 | 2016-04-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| EP2313110A1 (en) | 2008-08-05 | 2011-04-27 | Boehringer Ingelheim International GmbH | Effectors of par-2 activation and their use in the modulation of inflammation |
| EP2313364B1 (en) * | 2008-08-07 | 2020-09-02 | Idexx Laboratories, Inc. | Methods for detecting symmetrical demethylarginine |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| JP5932670B2 (ja) * | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | ｐＨ依存性の抗原結合を有する抗体 |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| US9540449B2 (en) * | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| CA2953714C (en) | 2014-06-30 | 2021-05-18 | Ralf Guenther | Anti-tnfa antibodies with ph-dependent antigen binding |
| MX2019010802A (es) * | 2017-03-16 | 2019-10-30 | Medimmune Ltd | Anticuerpos anti-par2 y usos de los mismos. |
-
2018
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/es unknown
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/zh active Active
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/ja active Active
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 PT PT187141858T patent/PT3596125T/pt unknown
- 2018-03-16 DK DK18714185.8T patent/DK3596125T3/da active
- 2018-03-16 IL IL269134A patent/IL269134B2/en unknown
- 2018-03-16 UA UAA201910275A patent/UA125757C2/uk unknown
- 2018-03-16 BR BR112019018752-9A patent/BR112019018752A2/pt unknown
- 2018-03-16 EP EP18714185.8A patent/EP3596125B1/en active Active
- 2018-03-16 EP EP25204633.9A patent/EP4681726A3/en active Pending
- 2018-03-16 CR CR20190417A patent/CR20190417A/es unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 MA MA049886A patent/MA49886A/fr unknown
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 KR KR1020197030092A patent/KR102711884B1/ko active Active
- 2018-03-16 LT LTEPPCT/EP2018/056776T patent/LT3596125T/lt unknown
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
- 2018-03-16 TW TW107109179A patent/TWI788332B/zh active
- 2018-03-16 PL PL18714185.8T patent/PL3596125T3/pl unknown
- 2018-03-16 HR HRP20251643TT patent/HRP20251643T1/hr unknown
- 2018-03-16 ES ES18714185T patent/ES3056721T3/es active Active
- 2018-03-16 SI SI201831278T patent/SI3596125T1/sl unknown
- 2018-03-16 CA CA3055251A patent/CA3055251A1/en active Pending
- 2018-03-16 FI FIEP18714185.8T patent/FI3596125T3/fi active
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/en not_active Ceased
- 2018-03-16 RS RS20251336A patent/RS67581B1/sr unknown
-
2019
- 2019-09-11 ZA ZA2019/06004A patent/ZA201906004B/en unknown
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/es unknown
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/es unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983B2/en active Active
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/ja active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en not_active Abandoned
-
2025
- 2025-03-18 JP JP2025043151A patent/JP2025102812A/ja active Pending
- 2025-05-27 AU AU2025203947A patent/AU2025203947A1/en active Pending
- 2025-09-19 US US19/334,502 patent/US20260078180A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102905B (en) | Anti-galectin-9 antibodies and uses thereof | |
| ZA202101318B (en) | Anti-phf-tau antibodies and uses thereof | |
| IL271477A (en) | Anti-cd166 antibodies and their uses | |
| IL267942B (en) | Anti-cd73 antibodies and uses thereof | |
| IL268734A (en) | Anti-LAG-3 antibodies and uses thereof | |
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| IL266738A (en) | Novel antibodies and their uses | |
| IL268206A (en) | Antibodies directed against bcma and their use | |
| IL264970A (en) | Anti-tim-3 antibodies and their use | |
| IL269134A (en) | Antibodies against PAR2 and their use | |
| SG11201808632YA (en) | Anti-pacap antibodies and uses thereof | |
| ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
| IL273157A (en) | Antibodies specific to AXL and their uses | |
| IL272476A (en) | Anti-Apelin antibodies and their uses | |
| IL278466B1 (en) | Anti-DLL3 antibodies and their uses | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| IL266082A (en) | Anti-chikv antibodies and their use | |
| IL266049A (en) | Antibodies against o1 and their uses | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| IL274202A (en) | Antibodies against Glyco-Moc1 and uses thereof | |
| IL264417A (en) | Anti-o2 antibodies and their uses | |
| GB201712032D0 (en) | Antibodies and uses thereof | |
| SG11202003585VA (en) | Anti-vista antibody and use thereof | |
| ZA201906248B (en) | Anti-ceacam1 antibody and use thereof |